Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06941662 · ClinicalTrials.gov registry record
Huntington's Disease Biobank: Advancing Remote Monitoring and Deep Phenotyping
A clinical trial of Huntington Disease, sponsored by Stanford University.
- Recruiting
- Registry status
- 200
- Enrollment target
- 1
- Study location
NCT06941662: Recruiting study of Huntington Disease, sponsored by Stanford University.
NCT06941662 is a study of Huntington Disease that is actively recruiting participants, run by Stanford University. The registered enrollment target is 200 participants, below the 630-participant average among 35 other Huntington Disease trials with a reported enrollment target (68% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06941662, a study of Huntington Disease, is actively recruiting participants, sponsored by Stanford University.
- RECRUITING
- Registry status
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
This observational study aims to identify novel biomarkers of disease onset and progression in Huntington's disease by integrating remote monitoring with fluid biomarkers. Using video-based computer vision and mobile app-based cognitive assessments combined with machine learning algorithms, we aim to develop markers that can be used by Huntington's disease patients at home. Using machine learning to analyze videos of movement will capture the movements with an accuracy that will be as good as seeing an expert neurologist. These individualized markers can be followed over time to evaluate symptoms onset and change. The study will track disease progression and correlate these digital markers with changes in plasma and cerebrospinal fluid. The ultimate goal is to advance biomarker discovery and therapeutic development for Huntington's disease. The study includes one in-person visit per year. A remote visit via Zoom or Facetime (15 min) every three months to record videos of movement. We can also share cutting-edge wristbands and a mobile phone app.
Primary Outcome
Neurological exam with a neurologist to document the motor exam
Conditions Studied
Interventions
- DIAGNOSTIC_TEST computer vision, remote monitoring, blood, urine, wrist bands, mobile-app
Study Locations (1)
California
- Stanford University - Palo Alto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2024-06-01 |
| Est. Completion | 2035-12 |
What NCT06941662 shows while recruiting
NCT06941662 is an observational study that tracks outcomes without assigning an intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 630-participant average among 35 other Huntington Disease trials with a reported enrollment target (68% lower).
The record links to 1 condition, with Huntington Disease appearing as the primary indexed condition, and to 1 intervention - of which computer vision, remote monitoring, blood, urine, wrist bands, mobile-app is the first listed.
NCT06941662 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06941662 about?
NCT06941662 is a clinical study titled "Huntington's Disease Biobank: Advancing Remote Monitoring and Deep Phenotyping". This observational study aims to identify novel biomarkers of disease onset and progression in Huntington's disease by integrating remote monitoring with fluid biomarkers. Using video-based computer vision and mobile app-based cognitive assessments combined with machine learning algorithms, we aim t...
What is the current status of trial NCT06941662?
This trial is currently recruiting. The enrollment target is 200 participants. The study started on 2024-06-01. Estimated completion is 2035-12.
What conditions does trial NCT06941662 study?
This clinical trial studies the following conditions: Huntington Disease.
What interventions are being tested in trial NCT06941662?
The interventions under investigation include: computer vision, remote monitoring, blood, urine, wrist bands, mobile-app (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06941662?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06941662 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Huntington Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06941662's enrollment target sits among peer trials
200 15th of 35 higher than 21 of 35 other Huntington Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Huntington Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Modification of Threat Interpretation Bias to Reduce Anxiety in Neurodegenerative Movement Disorders (Aim 3)
RECRUITING · NA
-
Longitudinal Endpoint Assessment of Disease Burden in HD
RECRUITING
-
Frequency of Selected Single Nucleotide Polymorphisms in Huntington Disease Gene Expansion Carriers
RECRUITING
-
Extracellular Vesicles for HD
RECRUITING
-
A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease
RECRUITING · Phase 3
-
A Randomized Study of SPK-10001 Gene Therapy in Participants With Huntington's Disease
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI